JP2024523003A - Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法 - Google Patents

Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法 Download PDF

Info

Publication number
JP2024523003A
JP2024523003A JP2023574779A JP2023574779A JP2024523003A JP 2024523003 A JP2024523003 A JP 2024523003A JP 2023574779 A JP2023574779 A JP 2023574779A JP 2023574779 A JP2023574779 A JP 2023574779A JP 2024523003 A JP2024523003 A JP 2024523003A
Authority
JP
Japan
Prior art keywords
dll3
dose
administered
domain
targeting trispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523003A5 (https=
Inventor
ウェッシュ，ホルガー
サン，リーピン
Original Assignee
ハープーン セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハープーン セラピューティクス，インク． filed Critical ハープーン セラピューティクス，インク．
Publication of JP2024523003A publication Critical patent/JP2024523003A/ja
Publication of JP2024523003A5 publication Critical patent/JP2024523003A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023574779A 2021-06-03 2022-06-02 Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法 Pending JP2024523003A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163196619P 2021-06-03 2021-06-03
US63/196,619 2021-06-03
US202163288939P 2021-12-13 2021-12-13
US63/288,939 2021-12-13
US202263345150P 2022-05-24 2022-05-24
US63/345,150 2022-05-24
PCT/US2022/031919 WO2022256500A2 (en) 2021-06-03 2022-06-02 Dll3 targeting trispecific proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2024523003A true JP2024523003A (ja) 2024-06-25
JP2024523003A5 JP2024523003A5 (https=) 2025-06-10

Family

ID=84323573

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574779A Pending JP2024523003A (ja) 2021-06-03 2022-06-02 Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法

Country Status (6)

Country Link
US (1) US20240218063A1 (https=)
EP (1) EP4347637A4 (https=)
JP (1) JP2024523003A (https=)
AU (1) AU2022286407A1 (https=)
CA (1) CA3220884A1 (https=)
WO (1) WO2022256500A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2024215875A2 (en) * 2023-04-14 2024-10-17 Harpoon Therapeutics, Inc. Compositions and methods for enhancing anti-tumor immunity
EP4712977A1 (en) 2023-05-19 2026-03-25 Boehringer Ingelheim International GmbH Uses of t cell engaging proteins in the treatment of cancer
WO2025085761A1 (en) * 2023-10-19 2025-04-24 Harpoon Therapeutics, Inc. Dll3 targeting trispecific proteins and methods of use
WO2025201493A1 (zh) * 2024-03-29 2025-10-02 诺纳生物（苏州）有限公司 Dll3结合分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020023330A2 (pt) * 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
US10815311B2 (en) * 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use

Also Published As

Publication number Publication date
CA3220884A1 (en) 2022-12-08
WO2022256500A3 (en) 2023-01-19
EP4347637A4 (en) 2025-04-16
US20240218063A1 (en) 2024-07-04
AU2022286407A1 (en) 2024-01-04
WO2022256500A2 (en) 2022-12-08
EP4347637A2 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
JP7659669B2 (ja) Ｄｌｌ３結合タンパク質および使用方法
JP7507790B2 (ja) ＥｐＣＡＭ結合タンパク質および使用方法
US11180563B2 (en) FLT3 binding proteins and methods of use
KR102569133B1 (ko) 삼중특이적 단백질 및 사용 방법
JP2024523003A (ja) Ｄｌｌ３標的化三重特異性タンパク質およびそれらの使用方法
US12195544B2 (en) EGFR binding proteins and methods of use
JP2024520727A (ja) Ｂｃｍａ標的化三重特異性タンパク質およびその使用
WO2025085761A1 (en) Dll3 targeting trispecific proteins and methods of use
AU2024363454A1 (en) Dll3 targeting trispecific proteins and methods of use
WO2024215875A2 (en) Compositions and methods for enhancing anti-tumor immunity
CN118159554A (zh) Dll3靶向三特异性蛋白及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250602